AC-101

Phase 2Small molecule

AAccro Bioscience (Suzhou) Limited

AC-101 is one of 48 small molecule programs targeting Ulcerative Colitis (UC). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ulcerative Colitis (UC)Not yet recruiting

Ulcerative ColitisRecruiting

Ulcerative Colitis (UC)Phase 2

Not yet recruiting

Ulcerative ColitisPhase 2

Recruiting

Competition

Competitive Landscape

104 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Humira

Novartis

Phase 3

19 2

Stelara

Johnson & Johnson

Phase 3

11 3

Velsipity

Pfizer

Phase 3

10 4

Skyrizi

AbbVie

Phase 3

6 5

Jyseleca

Gilead

Phase 3

6 6

Tremfya

Johnson & Johnson

Phase 3

2 7

Mounjaro

Eli Lilly

Phase 3

1 8

Mesalazine

Ferring

Phase 3

17 9

Duvakitug

Sanofi

Phase 3

2 10

Open-Label

Jazz Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Ulcerative Colitis

NCT07083193

Q1 2028

Phase 2Not yet recruiting

Ulcerative Colitis (UC)

NCT07755241

Clinical

Trials by Indication[1]

Ulcerative Colitis1 trial

A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis

Recruiting·AAccro Bioscience (Suzhou) Limited·Phase 1/2·NCT07083193·24 enrolled

Ulcerative Colitis (UC)1 trial

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-finding Study to Evaluate the Efficacy and Safety of AC-101 Tablets in Patients With Moderately to Severely Active Ulcerative Colitis

Not yet recruiting·AAccro Bioscience (Suzhou) Limited·Phase 2·NCT07755241·153 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AC-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AC-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AC-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Accro Bioscience (Suzhou) Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAccro Bioscience (Suzhou) Limited

AC-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2028

Trials by Indication[1]

Ulcerative Colitis1 trial

Ulcerative Colitis (UC)1 trial

References

Drug Info

Quick Facts

Related News